NCT00680953 - Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis | Biotech Hunter

Enrollment

1,262

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions

Osteoporosis

Interventions

DRUG

Denosumab

Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

DRUG

Placebo

Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).

DRUG

Alendronate sodium hydrate

Oral tablet once a week for 24 months

Trial Locations (4)

Fukuoka

Osaka

Sapporo

Tokyo